Sunday, December 3, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Professor and Director
Department of Clinical Hematology
Peter MacCallum Cancer Centre
Royal Melbourne Hospital
Melbourne, Australia
Consultant Hematologist
Oxford Cancer and Haematology Centre
Churchill Hospital
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Professor
Medical Director
Comprehensive Cancer Center Ulm
Head
Early Clinical Trials Unit
Head
Division of CLL
Department of Internal Medicine III
Ulm University
Ulm, Germany
Professor of Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity is intended for a global international audience of hematologists and oncologists who manage patients with B-cell malignancies.
The goal of this activity is for the learner to be better able to examine recent data with emerging Bruton tyrosine kinase (BTK) inhibitors and how this may necessitate changes in practice when managing patients with chronic lymphocytic leukemia (CLL).
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
Professor and Director
Department of Clinical Hematology
Peter MacCallum Cancer Centre
Royal Melbourne Hospital
Melbourne, Australia
Consultant Hematologist
Oxford Cancer and Haematology Centre
Churchill Hospital
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Professor
Medical Director
Comprehensive Cancer Center Ulm
Head
Early Clinical Trials Unit
Head
Division of CLL
Department of Internal Medicine III
Ulm University
Ulm, Germany
Professor of Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 100% on the post-test.
Follow these steps to earn CME/CE credit*:
Read the target audience, learning objectives, and author disclosures.
Study the educational content.
Access the post-test webpage at the URL here medscape.org/anthology/alzheimers-timely-identification or via the provided QR code.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 4/5/2022
Valid for credit through: 4/5/2023, 11:59 PM EST
processing....
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
